A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan

This tumor-naïve MRD assay demonstrated clinically meaningful performance at LMT and longitudinally, accurately predicting clinical recurrence. MRD status was a stronger prognostic biomarker for disease-free survival compared with standard-of-care carcinoembryonic antigen.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2024-11-08
DOI
https://doi.org/10.1158/1078-0432.ccr-24-2396
Citations
14
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
3.99
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan

Chithra Sangli, Richard Blidner, Daniel Neems, Christine Lo et al.
14 citations
Clinical Cancer Research
Cancer Genomics and Diagnostics
3.99
article

A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan

Chithra Sangli, Richard Blidner, Daniel Neems, Christine Lo, Robert Tell, Jason Yamada-Hanff, Yoshiaki Nakamura, Ichiro Takemasa, Anne Sonnenschein, Jun Watanabe, Daisuke Kotani, Dana F. DeSantis, Kentaro Yamazaki, Farahnaz Islam, Hideaki Bando, Halla Nimeiri, Terri M. Driessen, Jonathan E. Freaney, Masahito Kotaka, Kristiyana Kaneva, Saori Mishima, Takayuki Yoshino, Eiji Oki, Hiroya Taniguchi, Hala Boulos, Takeshi Kato, Seung Won Hyun, Kate Sasser
article en
14 citations

Abstract

This tumor-naïve MRD assay demonstrated clinically meaningful performance at LMT and longitudinally, accurately predicting clinical recurrence. MRD status was a stronger prognostic biomarker for disease-free survival compared with standard-of-care carcinoembryonic antigen.

Clinical Cancer ResearchVol. 31(2)
Kansai Medical University (JP), Kyushu University (JP), Sapporo Medical University (JP), Yokohama City University Medical Center (JP), Kanagawa Prefectural Hospital Organization (JP), Shizuoka Cancer Center (JP), Osaka National Hospital (JP), Tempus Labs (United States) (US), Aichi Cancer Center (JP), National Cancer Center Hospital East (JP), Yokohama City University (JP)
Good health and well-being
Openalex Percentile: Top 5%
Cancer Genomics and Diagnostics
3.99
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.